Navigation Links
Hepatitis C responds best to combo of ribavirin and interferon, study concludes

A combination of the drugs ribavirin and interferon is more effective in treating hepatitis C than using interferon alone, but it also increases the risk of side effects, according to a new systematic review of recent evidence.

"Adding ribavirin to any type of interferon should be considered the treatment of choice for patients with hepatitis C," conclude Jesper Brok, M.D., and colleagues at Copenhagen University Hospital.

However, the authors caution that only one in four patients treated with the combination therapy actually had a sustained response.

The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Hepatitis C is inflammation of the liver caused by the hepatitis C virus (HCV). It is transmitted primarily by blood-to-blood contact through a variety of means such as sexual contact, intravenous drug use and needle stick accidents. The disease progresses slowly over 10 to 30 years, causing inflammation and severe scarring of the liver. If untreated, it can lead to liver failure, liver cancer and death.

According to the Centers for Disease Control and Prevention, 170 million people worldwide are infected with HCV, and in the United States, alcoholic liver disease and chronic hepatitis C are the leading causes of cirrhosis. An additional estimated 25,000 new cases of HCV occur in the United States each year.

Interferons have been proven effective in treating HCV by enhancing certain cellular activities such their a bility to kill virus cells and inhibiting the ability of viruses to make new copies of themselves and proliferate.

Ribavirin belongs to a class of drugs called nucleoside analogues, which includes some anti-HIV drugs such as AZT (zidovudine). Ribavirin used alone does not have any effect on HCV but in combination with interferon it appears to boost the immune system and help slow virus replication.

The researchers were measuring failure to respond adequately to treatment under each course of treatment.

In tests for presence of the virus among those who had never been treated for the disease, 83 percent of those on interferon did not respond after six months, compared to 58 percent of those getting interferon plus ribavarin.

Among those who had relapsed after previous treatment 87 percent of interferon-only patients did not respond, compared to 51 percent who were on combination therapy.

Of the patients who had not responded at all to previous therapy, 95 percent of the interferon patients did not respond, compared to 81 percent of those getting both drugs.

Other measures reported by the researchers included patient status at the end of treatment, quality of life and whether patients had a reduction in liver inflammation. Patients who had combination therapy did better in all categories. Side effects, however, were much more common in the combination therapy across all groups than in the interferon-alone group.

The most frequent side effect was anemia, which occurred in 22 percent of cases of combination recipients and less than 1 percent of the interferon group. Other side effects that occurred much more frequently in the combination therapy patients included a reduced number of white blood cells; skin disorders such as dry skin and rash; stomach complaints such as lack of appetite, nausea and indigestion; infections; insomnia; difficulty breathing, cough and fatigue.

"The beneficial effect of adding ri bavirin to interferon is not fully understood," the authors conclude. "Ribavirin might have an independent beneficial effect on chronic hepatitis C, in addition to interferon, or might have a beneficial effect on patients who do not respond to interferon. Alternatively, ribavirin may (heighten) some of the effects of interferon or vice versa."


'"/>

Source:Center for the Advancement of Health


Related biology news :

1. Scientists Replicate Hepatitis C Virus in Laboratory
2. Norovirus, AIDS vaccine and Hepatitis Virus
3. UCLA study assesses cost-effectiveness of Hepatitis B drugs
4. Natural Killers Could Lead to New Hepatitis Treatments
5. FDA Approves New Treatment for Chronic Hepatitis B
6. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
7. Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied
8. Hepatitis C complicated by morphine withdrawal
9. Hepatitis B accounts for 40 percent of missing Asian women
10. Hepatitis C therapy: Inhibiting newly discovered microDNA molecule
11. Hepatitis E takes a piggyback
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... MA (PRWEB) , ... December 02, 2016 , ... Robots ... Light Event on December 3rd, 2016. The event, which is held on the ... work with helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering ...
(Date:12/2/2016)... December 2, 2016 The immunohistochemistry (IHC) ... at a CAGR of 7.3% during the forecast period of 2016 ... diagnostic laboratories segment accounted for the largest share of immunohistochemistry (IHC) ... , ... global immunohistochemistry (IHC) market spread across 225 pages, profiling 10 companies ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a brand ... a flexure design that ensures high alignment accuracy by preventing unwanted shaft rotation. ... suited where extreme precision is required, such as in medical equipment, laboratory instrumentation, ...
(Date:11/30/2016)... , November 30, 2016 ... a few players hold a dominant share in the ... River Laboratories International, Inc., and Merck KGaA, held a ... 2015. Transparency Market Research observes that these companies are ... on development products that are do not require rabbit ...
Breaking Biology Technology: